Table 2.
Clinical data and laboratory results of three groups of subjects, mean (SD)
| Parameters | Control group (N = 40) | Low-risk CAP group (N = 42) | Medium–high-risk CAP group (N = 40) | F/χ 2 | P-value |
|---|---|---|---|---|---|
| Gender: male (female) | 25 (15) | 23 (19) | 24 (16) | 0.531 | 0.767 |
| Age: year, mean (SD) | 75.93 (8.69) | 76.67 (7.97) | 79.40 (10.42) | 1.099 | 0.199 |
| WBC (109 L−1) | 6.51 (1.69) | 7.35 (4.10) | 10.38 (4.81)*# | 11.657 | <0.001 |
| N (109 L−1) | 3.71 (1.32) | 5.25 (4.12) | 8.81 (4.57)*# | 20.658 | <0.001 |
| L (109 L−1) | 2.24 (0.73) | 1.35 (0.54)* | 0.99 (0.68)*# | 38.833 | <0.001 |
| NLR | 1.77 (0.73) | 5.25 (6.26)* | 12.20 (8.52)*# | 30.162 | <0.001 |
| PLT (109 L−1) | 247.00 (48.67) | 196.12 (67.99)* | 181.58 (83.22)* | 10.207 | <0.001 |
| PLR | 120.16 (43.49) | 168.56 (85.84)* | 241.23 (155.69)*# | 13.387 | <0.001 |
| D–D (mg L−1) | 0.13 (0.11) | 3.75 (5.70)* | 14.43 (20.08)*# | 15.462 | <0.001 |
| ALB (g L−1) | 47.36 (2.88) | 36.16 (4.70)* | 33.13 (6.19)*# | 98.535 | <0.001 |
| hs-CRP (mg L−1) | 1.80 (3.93) | 22.58 (20.72)* | 41.74 (17.43)*# | 63.182 | <0.001 |
| CAR (mg g−1) | 0.04 (0.09) | 0.68 (0.65)* | 1.37 (0.69)*# | 58.285 | <0.001 |
| FIB (mg L−1) | 2892.75 (891.77) | 3741.43 (1431.05)* | 4403.25 (1507.48)* | 13.405 | <0.001 |
| FAR (mg g−1) | 61.47 (21.06) | 107.23 (49.26)* | 141.38 (66.02)*# | 26.690 | <0.001 |
Note: * P < 0.05, when compared with the normal control group; # P < 0.05, when compared with low-risk CAP group.